 |
|
Interleukin 10 Treatment of Psoriasis
Clinical Results of a Phase 2 Trial
Khusru Asadullah, MD;
Wolf-Dietrich Döcke, MD;
Merle Ebeling;
Markus Friedrich, MD;
Gudrun Belbe;
Heike Audring, MD;
Hans-Dieter Volk, MD;
Wolfram Sterry, MD
Arch Dermatol. 1999;135:187-192.
Objective To determine the safety and clinical effects of interleukin 10 (IL-10) treatment of psoriasis.
Design and Methods In an open-label phase 2 trial, 10 patients with psoriasis subcutaneously received recombinant human IL-10 over a 7-week period in a dosage of 8 µg/kg daily (n=5) or 20 µg/kg 3 times per week (n=5). Patients were followed up for an additional 5 weeks.
Results The treatment was well tolerated. Antipsoriatic effects were found in all but 1 patient. A significant decrease of the psoriasis area and severity index by 55.3% ± 11.5% (mean ± SEM) was observed (P<.02). The antipsoriatic efficiency was confirmed by histological examination. Heterogeneity in the effectiveness was found among the patients, but seems to be independent of the dosage regimen. However, a tendency to a better response was found in the patients who received 20-µg/kg IL-10 3 times per week. Decreasing response in the delayed-type hypersensitivity reaction against recall antigens indicated immunosuppressive effects. Moderate effects on hematopoietic cells were observed.
Conclusions Our data suggest that IL-10 therapy for psoriasis is safe and possibly clinically effective. Consequently, its value in psoriasis and similar immune diseases should be further determined. Dose-finding, placebo-controlled, double-blind trials are necessary now.
From the Department of Dermatology (Drs Asadullah, Friedrich, Audring, and Sterry, and Ms Ebeling) and Institute of Medical Immunology (Drs Döcke and Volk, and Ms Belbe), University Hospital Charité, Berlin Humboldt University, Berlin, Germany.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
In Vivo IL-10 Gene Delivery Suppresses Airway Eosinophilia and Hyperreactivity by Down-Regulating APC Functions and Migration without Impairing the Antigen-Specific Systemic Immune Response in a Mouse Model of Allergic Airway Inflammation
Nakagome et al.
J. Immunol. 2005;174:6955-6966.
ABSTRACT
| FULL TEXT
CD4+ T Cell-Associated Pathophysiology Critically Depends on CD18 Gene Dose Effects in a Murine Model of Psoriasis
Kess et al.
J. Immunol. 2003;171:5697-5706.
ABSTRACT
| FULL TEXT
Interleukin-10 Induction of Nitric-oxide Synthase Expression Attenuates CD40-mediated Interleukin-12 Synthesis in Human Endothelial Cells
Cattaruzza et al.
J. Biol. Chem. 2003;278:37874-37880.
ABSTRACT
| FULL TEXT
Functional Cooperation of Simian Virus 40 Promoter Factor 1 and CCAAT/Enhancer-Binding Protein {beta} and {delta} in Lipopolysaccharide-Induced Gene Activation of IL-10 in Mouse Macrophages
Liu et al.
J. Immunol. 2003;171:821-828.
ABSTRACT
| FULL TEXT
Interleukin-10 Therapy--Review of a New Approach
Asadullah et al.
Pharmacol. Rev. 2003;55:241-269.
ABSTRACT
| FULL TEXT
Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential
Von der Thusen et al.
Pharmacol. Rev. 2003;55:133-166.
ABSTRACT
| FULL TEXT
Local Delivery of the Viral Interleukin-10 Gene Suppresses Tissue Inflammation in Murine Pneumocystis carinii Infection
Ruan et al.
Infect. Immun. 2002;70:6107-6113.
ABSTRACT
| FULL TEXT
Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10
Kimball et al.
Arch Dermatol 2002;138:1341-1346.
ABSTRACT
| FULL TEXT
Biologic Therapy for Psoriasis: The New Therapeutic Frontier
Singri et al.
Arch Dermatol 2002;138:657-663.
ABSTRACT
| FULL TEXT
IL-10 Improves Skin Disease and Modulates Endothelial Activation and Leukocyte Effector Function in Patients with Psoriatic Arthritis
McInnes et al.
J. Immunol. 2001;167:4075-4082.
ABSTRACT
| FULL TEXT
Decision Support Is Changing Health Care
Kvedar and Menn
Arch Dermatol 2000;136:249-250.
FULL TEXT
|
